Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Dose Escalation Study of YL-13027 Monotherapy in Subjects With Advanced Stage Solid Tumors

NCT03869632 is registered in ClinicalTrials.gov with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT03869632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03869632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Dose Escalation Study of YL-13027 Monotherapy in Subjects With Advanced Stage Solid Tumors
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 19, 2019
Completion date
June 30, 2022
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors